Skip to content

Establishment of intelligent decision-making system for treatment of neurological impairment in cerebrovascular disease

Establishment of intelligent decision-making system for treatment of neurological impairment in cerebrovascular disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026492
Enrollment
Unknown
Registered
2019-10-12
Start date
2019-03-01
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Case series:Adjustment of medication

Sponsors

The Second Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years old; 2. Diagnosis of ischemic stroke (atherosclerotic cerebral infarction) or diagnosis of transient ischemic attack (diagnosis meets the criteria established by the Cerebrovascular Diseases Group of the Chinese Medical Association Neurology Branch in 2014); 3. Acute period of onset (2 weeks); 4. NIHSS score <=15 points; 5. Voluntarily participate in and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Cancer patients; 2. cerebral infarction of cardiogenic infarction, small vessel disease, other causes of cerebral infarction, unexplained cerebral infarction; 3. Patients with active stomach diseases; 4. Alteplase thrombolytic patients, as well as some cases requiring anticoagulation or dual antiplatelet (PCI); 5. Hemorrhagic stroke, mixed stroke and tumor stroke; 6. Received whole blood or platelet transfusion in the past two weeks, with coagulopathy or other blood diseases; 7, renal dysfunction (24 hours urine volume is less than 1000ml, and serum creatinine is greater than 180mmol / L, urine creatinine less than 5mmol/L); 8. Combined with serious heart, lung and liver system diseases; 9. The investigator judges patients with poor adherence and who are unable to complete long-term follow-up; 10. Currently involved in any clinical trial of research drugs or medical devices.

Design outcomes

Primary

MeasureTime frame
CYP2C19;11-dhTxB2;

Countries

China

Contacts

Public ContactYingping Yi

The Second Affiliated Hospital of Nanchang University

yyp66@126.com+86 13807089678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026